<DOC>
	<DOCNO>NCT02118064</DOCNO>
	<brief_summary>This study design evaluate ability G17DT slow arrest tumor growth patient refractory colon cancer previously treat Irinotecan-based chemotherapy .</brief_summary>
	<brief_title>Phase II Study Evaluate G17DT Combination With Irinotecan Patients With Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Have histologically confirm cancer colon rectum objective evidence distant metastasis Have measurable disease Have previously treat irinotecan base chemotherapy Have progressive metastatic disease irinotecan contain chemotherapy regimen ( alone combination ) metastatic colorectal cancer Be least 18 year age Have laboratory data specify : Aspartate aminotransferase ( AST ) ALT le 2.5 time upper limit normal Bilirubin le 1.5 mg/dL ( SI unit , 25.65 mol/L ) Creatinine le 1.5 mg/dL ( SI unit , 132 mol/L ) White blood cell ( WBC ) count great 3,000/mm3 Platelets great 100,000/mm3 Hemoglobin 9.5 g/dL ( SI unit , 5.9 mol/L ) International normalize ratio prothrombin time le 1.2 , activate partial thromboplastin time 5 second normal limit Have life expectancy least 3 month Have KPS score 70 great Use contraceptive method , sexually active Have ability understand requirement study , provide write informed consent , agree abide study restriction , agree return require assessment Be pregnant nursing Have symptomatic locally recurrent colorectal cancer Have active cancer addition metastatic colorectal cancer within last 5 year except curatively treat nonmelanomatous skin cancer Have receive prior anticancer immunotherapy Have central nervous system metastasis , whether treat Have bone metastasis sole manifestation metastatic colorectal cancer Have receive chemotherapy within previous 21 day Have major surgery within 21 day Have immunodeficiency ( primary acquire ) Have undergone bone marrow transplantation within last year Require chronic administration corticosteroid ; inhale corticosteroid asthma chronic obstructive pulmonary disease allow Use past 30 day concomitant use immunosuppressant , include systemic ( i.e. , oral inject ) corticosteroid Have participate clinical trial involve conventional investigational drug device within 21 day G17DT irinotecan administration Have contraindication irinotecan base therapy Have hypersensitivity diphtheria toxoid Use past 14 day chronic concomitant use proton pump inhibitor Have uncontrolled serious cardiovascular metabolic disease uncontrolled serious medical psychiatric illness Have condition likely detrimentally affect regular follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>G17DT</keyword>
	<keyword>irinotecan</keyword>
	<keyword>Colorectal Cancer</keyword>
</DOC>